New hope for elderly lung cancer patients: drug combo targets tough cases
NCT ID NCT07398560
First seen Feb 16, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This study is for elderly patients (65+) or those in poor health with small cell lung cancer. It tests a combination of two drugs—adebrelimab (an immunotherapy) and oral etoposide (chemotherapy)—to see if it can control the cancer and improve survival. The goal is to find a gentler but effective treatment option for patients who cannot tolerate standard therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Third Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.